A lthough generally considered to be safe, cardiac catheterization in patients with congenital heart disease (CHD), like all invasive procedures, is associated with a risk of adverse events. In certain types of interventional procedures, the risk of complications can be as high as 24%. 1 Although some adverse events are minor (eg, hematoma at the access site, transient arrhythmia not requiring intervention), more serious adverse events can and do occur. The NCDR's (National Cardiovascular Data Registry) Improving IMPACT Registry (Improving Pediatric and Adult Congenital Treatment) is the largest clinical registry of pediatric patients with and without CHD and adult patients with CHD undergoing diagnostic and interventional catheterization procedures. Currently, centers participating in IM-PACT receive quarterly reports on quality metrics, including the frequency of major adverse events (MAEs), compared with those of all other participating centers. These reports provide only crude adverse event rates, although some are stratified by diagnostic procedures and age, and a more comprehensive risk-standardization method is needed given the variability in clinical characteristics and types of treatments performed at different centers.
CHARM (Congenital Heart Disease Adjustment for Risk Method) was the first multicenter effort to risk standardize outcomes for congenital cardiac catheterization and identified 4 procedure-type risk categories, hemodynamic vulnerability factors, and age as critical for risk standardization. 2 In an effort to begin development of risk-standardization methodology for IMPACT, aspects of CHARM, including the derived procedure-type risk categories and markers of hemodynamic vulnerability, were directly applied to data from IMPACT for the outcome of an MAE as collected in the IMPACT Registry. 3 Based on this initial work, however, it was determined that these variables did not perform optimally within IMPACT for the defined outcome, and it was acknowledged that revising these important predictor variables was needed to more accurately risk-adjust MAEs before this model could be used for quality reporting back to sites participating in IMPACT. Toward this end, we sought to expand on initial work and develop a more robust risk-standardization methodology for reporting MAEs in the IMPACT Registry, including derivation of categories to define procedural risk and indicators of hemodynamic vulnerability using data collected in IMPACT. A refined risk model can be used to provide risk-standardized adverse event rates to institutions participating in IMPACT to provide a more accurate assessment of how each center's outcomes compare to those of other registry participants while taking into account patient acuity and procedural complexity at each center.
METHODS

Study Population
The IMPACT Registry is 1 of 8 hospital registries sponsored by the NCDR and the only one to collect data on pediatric patients (both with and without CHD) and adult patients with CHD undergoing diagnostic or interventional cardiac catheterization. The IMPACT Registry builds on several prior pediatric and congenital cardiology database initiatives 4 and has been previously described in detail. 5 In brief, IMPACT collects data on the prevalence, demographics, management, and in-hospital outcomes for patients at each of the participating centers. The nomenclature used in the IMPACT Registry is the International Pediatric and Congenital Cardiac Code. 6, 7 Data for IMPACT are collected using a standardized set of data elements and definitions and are subject to rigorous quality assurance standards, consistent with other NCDR registries. 8 Only data meeting prespecified criteria for completeness and accuracy are included in analytic datasets and used for quality reporting back to the sites. The current study used data from IMPACT v1.0.1. A comprehensive description of the IMPACT Registry version v1.0.1 data elements and definitions is available at https://www.ncdr. com/WebNCDR/impact/home/datacollection.
Study Outcome
The primary outcome of interest was the occurrence of an MAE. A committee of 8 subject matter experts convened,
Clinical Perspective
What Is New?
• Building on previous risk-standardization efforts, a risk-standardization methodology for the NCDR's (National Cardiovascular Data Registry) IMPACT Registry (Improving Pediatric and Adult Congenital Treatment) was developed.
• New procedure-type risk categories and markers of hemodynamic vulnerability were developed using IMPACT data to improve the ability to risk-standardize outcomes.
• The risk-standardization tool adjusts for proceduretype risk category, hemodynamic vulnerability, single-ventricle physiology, coagulation disorder, and renal insufficiency.
What Are the Clinical Implications?
• Currently, centers participating in the IMPACT Registry receive quarterly reports that present crude or unadjusted rates of adverse events. • This risk model will be directly applied to IMPACT data to provide participating centers with riskadjusted rates of major adverse events.
• By understanding how each center's performance compares with that of other centers, individual institutions can identify areas for quality improvement and ultimately improve care for patients with congenital heart disease undergoing cardiac catheterization.
reviewed the IMPACT case report form, and determined which adverse events constituted MAEs to be the composite outcome of the multivariable model. Williams-Beuren syndrome), or medical comorbidities, including chronic lung disease, diabetes mellitus, hepatic disease, seizure disorder, sickle cell anemia, renal insufficiency, and coagulation disorders (defined as a hypercoagulable state with low prothrombin time/partial thromboplastin time and not secondary to any medication or hypocoagulable state with high prothrombin time/partial thromboplastin time, platelet count <100 000, or fibrinogen split products >10%, not secondary to any medications). Additionally, a history of stroke or sepsis and single-ventricle physiology was considered for inclusion in the model. Preprocedural medications, including patient need for prostaglandins or antiarrhythmic agents, were considered, as was hospital status (eg, patients brought from the outpatient setting versus those brought to the catheterization laboratory from the general inpatient floor or intensive care unit). Preprocedural mechanical support, including the need for intubation, extracorporeal membrane oxygenation, or left ventricular assist device, was also explored for association with the outcome.
Procedure-Type Risk Categories
Procedure-type risk categories were an additional candidate variable considered for model inclusion. The development of procedure-type risk categories was initially performed within the Congenital Cardiac Catheterization Project on Outcomes dataset and has been previously described in detail. 10 In brief, the risk associated with catheterization for CHD is known to vary based on several factors. The risk of diagnostic cardiac catheterization, for example, varies according to patient age. Furthermore, congenital cardiac catheterization encompasses a number of different types of interventional procedures, each of which is associated with a unique risk. The IMPACT Registry, for example, collects data on >200 different types of interventional procedures. Although it is necessary to adjust for the type of procedure performed, given the strong correlation with procedural risk, it is not feasible to adjust for each procedure individually. Procedure-type risk categories lump together procedures that represent similar risk, obviating the need to adjust for each individual procedure separately. Proceduretype risk groups represent a concept similar to risk categories used for congenital heart surgery. [11] [12] [13] Within the Congenital Cardiac Catheterization Project on Outcomes, this type of grouping has been done successfully, and 4 categories of procedural risk were established. These 4 categories were found to be the most important factor in the risk-adjustment methodology. 10 The 4 categories of procedural risk, developed within the Congenital Cardiac Catheterization Project on Outcomes, were used as part of the initial risk-standardization work for IMPACT. 3 However, the variable did not discriminate well in IMPACT, so new procedure-type risk categories were developed for the purposes of this work. Appendix I in the online-only Data Supplement contains a full description of the methods used for development of the new procedure-type risk groups. After combining empirical data with expert opinion, 6 categories of procedural risk were created (Table 1 and Table I in the online-only Data Supplement), with category 1 representing procedures of lowest risk and category 6 representing procedures of highest risk.
Hemodynamic Vulnerability Indicators
Based on previous studies identifying abnormal hemodynamics as a risk factor for experiencing an MAE after cardiac catheterization, the performance of previously developed indicators of hemodynamic vulnerability was rigorously explored, 2,14 as were other potential hemodynamic characteristics. The concept of hemodynamic vulnerability has been previously described in detail. 2, 14 In brief, within CHARM, 4 hemodynamic variables (eg, systemic ventricular end diastolic pressure, pulmonary artery pressure, systemic saturation, mixed venous saturation) were identified as being predictive of experiencing an MAE. Within CHARM, threshold values for each variable were created, designating a patient as "hemodynamically vulnerable." 2 The initial risk-standardization work for IMPACT incorporated these same 4 markers and thresholds of hemodynamic vulnerability. 3 However, to develop a risk-standardization model with maximal discriminatory ability, new criteria for hemodynamic vulnerability using data from IMPACT were explored for the purposes of this work. Appendix II in the online-only Data Supplement contains a full description of the methodology used for deriving the hemodynamic vulnerability indicators. Ultimately, 6 hemodynamic variables were selected and used to classify a patient as hemodynamically vulnerable. These variables included systemic saturation <95% (<78% for single-ventricle patients), mixed venous saturation <60% (<50% for single-ventricle patients), pulmonary artery systolic pressure ≥45 mm Hg (mean pressure ≥17 mm Hg for singleventricle patients), systemic ventricular end-diastolic pressure ≥18 mm Hg, pulmonary to systemic flow ratio (Qp:Qs) >1.5, and pulmonary vascular resistance >3 Wood units.
Next, the most appropriate ways to incorporate the individual hemodynamic variables into the final multivariable model were determined. Within CHARM, a composite score was created, and each patient was assigned a score based on the number of abnormal hemodynamic parameters present (0, 1, ≥2).
2 In contrast, in the initial risk-standardization work for IMPACT, a composite score was not created, and each hemodynamic variable was considered separately so that the independent contribution of each variable could be identified. 3 However, to address issues related to missing values, not uncommonly encountered for the hemodynamic variables, in this work, a composite and simplified hemodynamic variable was pursued in which patients were categorized based on the number of abnormal hemodynamic parameters present (0, 1, 2, or >2). Patients whose hemodynamic data were not reported were considered to have a normal value for that missing variable.
Statistical Analysis
Characteristics of those patients experiencing an adverse event were compared with characteristics of those not experiencing an adverse event using the Student t test for continuous variables and χ 2 for categorical variables. For model development, 70% of the population was randomly selected as the derivation cohort and the remaining 30% for a validation cohort. Baseline characteristics of the derivation and validation cohort were compared using the Student t test for continuous variables and χ 2 for categorical variables to ensure success of the randomization process. Within the derivation cohort, hierarchical multivariable logistic regression was used to identify characteristics predictive of experiencing an adverse event while also accounting for the clustered nature of the data (patients nested within hospitals). 15 Use of hierarchical models to estimate the log odds of experiencing an adverse event as a function of demographic and clinical variables (both fixed effects) and a random effect for each hospital also allowed us to assess for hospital variation in risk-standardized adverse event rates after accounting for patient case mix.
All candidate variables were considered for model inclusion. Multicollinearity between covariates was assessed for each variable before model inclusion. 16 To ensure parsimony and inclusion of only those variables that provided incremental prognostic value, the approximation of full model methodology for model reduction was used. 17 The contribution of each significant model predictor was ranked, and variables with the smallest contribution to the model were sequentially eliminated. This process was iterative until further variable elimination led to a >10% loss in model prediction as compared with the initial full model. A C-statistic, which quantifies the receiver operating characteristic curve, was calculated to assess model discrimination. 18 Model validation was performed in the remaining 30% of the cohort using observed versus predicted plots. Calibration in the validation cohort (eg, agreement between predicted and observed outcomes) was assessed by plotting observed rates versus mean predicted probabilities within deciles of predicted risk. For wellcalibrated models, the slope should approximate 1.0 with an intercept of 0.0, both of which were explicitly tested. 19 All study analyses were performed with SAS 9.4 (SAS Institute) and R version 2.15.0. 20 Aside from the hemodynamic variables, the frequency of missing data was low (<1%). Missing data were handled using imputation, using the most frequent category for categorical variables and mean value for continuous variables. Less than 1% of records were missing data regarding the specific type of procedure performed. These procedures had an event rate of 10.8% and were therefore imputed into category 4, a category of moderate risk with procedures whose event rate was similar. The study was conducted on deidentified quality improvement registry data and did not meet criteria for the requirement of informed consent. Waiver of written informed consent and authorization for this study was granted by Chesapeake Research Review Incorporated. The IMPACT Registry's Research and Publications Committee approved the final manuscript draft.
RESULTS
Population
From January 2011 through March 2014, 39 725 diagnostic or interventional cardiac catheterization procedures were performed at 74 US centers. Among the study population, 27 868 were randomly selected for derivation cohort and 11 857 selected for the validation cohort. Baseline characteristics of the derivation and validation cohorts were similar (Tables II and III in the online-only Data Supplement). The mean age of the overall study cohort was 9.7±12.7 years (median, 5.0 years, interquartile range, 1.0-14.0 years). A minority of the patients (6.2%) were <30 days of age. Approximately 1 in 10 patients had a reportable genetic condition (as outlined earlier). Nearly 1 out of every 5 patients had single-ventricle physiology. The most common comorbid condition was chronic lung disease, occurring in 6.2% of patients.
Predictors of a Major Adverse Event
Overall, an MAE occurred in 2832 (7.1%) cases. Occurrence of an MAE was similar in the derivation and validation cohorts (7.1% versus 7.2%, P=0.84). The most common MAEs were bleeding (1.4%), arrhythmia requiring antiarrhythmic medication (1.0%), and death during the hospital admission after catheterization (2.0%). The remainder of adverse events occurred in <1% of cases (Table IV in the online-only Data Supplement). Tables 2 and 3 compare baseline characteristics of those experiencing an adverse event with characteristics of those not experiencing an adverse event among the derivation cohort. Neonates were more likely to experience an adverse event compared with children and adults (22.2% of neonates versus 4.3% of children and 5.3% of adults). Patients with a genetic condition were more likely to experience an adverse event compared with those without a documented genetic syndrome (10.0% versus 6.8%). Those with single-ventricle anatomy or physiology were more likely to experience an adverse event (10.3% versus 6.4%), as were those with another comorbid condition in addition to their CHD (9.4% versus 6.7%). Patients requiring antiarrhythmic agents, prostaglandins, or extracorporeal membrane oxygenation before their procedure were also more likely to experience an adverse event compared with those who did not. Furthermore, in univariate analysis, patients undergoing higher risk procedures were more likely to experience an adverse event. Last, patients experiencing an adverse event were more likely to have abnormal hemodynamics, as characterized by lower systemic or mixed venous saturations and higher pulmonary artery pressures, systemic ventricular end diastolic pressures, pulmonary to systemic flow ratios, and pulmonary vascular resistance.
After multivariable adjustment, the variables selected for inclusion in the final multivariable model included age, presence of a genetic condition, chronic lung disease, diabetes mellitus, hepatic disease, seizure disorder, sickle cell anemia, history of stroke, proceduretype risk category, hemodynamic vulnerability, renal insufficiency, coagulation disorder, and single-ventricle physiology, resulting in a model C-statistic of 0.759 (Table 4) . To create a more parsimonious model, elimination of variables was performed to create a reduced model that had a predictive value within 10% predictive value of the full model. The variables in the final reduced model included single-ventricle physiology, coagulation disorder, renal insufficiency, hemodynamic vulnerability, and procedure-type risk category (Table 4 and Figure 1) . The final reduced model discriminated well (C-statistic 0.756).
Using the independent validation cohort, the model was tested and found to have similar discrimination (Cstatistic 0.752). Model calibration was confirmed with observed versus predicted plots, with a slope of 0.97 (standard error, 0.04; P value [for difference from 1] =0.53) and an intercept of 0.007 (standard error, 0.12; P value [for difference from 0] =0.95) (Figure 2 ).
DISCUSSION
Using the large, multicenter IMPACT Registry, a risk model for standardization of MAEs after catheterization of pediatric and adult patients with CHD was developed. This effort required new procedure-type risk categories and markers of hemodynamic vulnerability, which improve the model's predictive ability. After adjusting for procedure-type risk category, hemodynamic vulnerability, and medical comorbidities, including single-ventricle physiology, coagulation disorder, and renal insufficiency, the model proved to have good discrimination and calibration in a randomly selected validation EDP indicates end diastolic pressure; MPA, main pulmonary artery; MV, mixed venous; PA, pulmonary artery; PVR, pulmonary vascular resistance; and SV, single ventricle. *10 508 patients (825 with and 9683 without a major adverse event) with missing information for systemic ventricular EDP.
†6422 patients (715 with and 5707 without a major adverse event) with missing information for Qp:Qs.
‡7907 patients (847 with and 7060 without a major adverse event) with missing information for PVR index.
§445 patients (75 with and 370 without adverse events) with missing information for SV systemic saturation.
¶743 patients (143 with and 600 without adverse events) with missing information for SV mixed venous saturation.
‖1185 patients (193 with and 992 without adverse events) with missing information for SV MPA mean pressure. **2220 patients (183 with and 2037 without adverse events) with missing information for non-SV systemic saturation.
† †3046 patients (299 with and 2747 without adverse events) with missing information for non-SV mixed venous saturation.
‡ ‡4367 patients (424 with and 3943 without adverse events) with missing information for non-SV MPA systolic pressure.
§ §2677 patients (259 with and 2418 without a major adverse event) with missing information for systemic saturation.
¶ ¶3801 patients (442 with and 3359 without a major adverse event) with missing information for mixed venous saturation.
‖‖5625 patients (620 with and 5005 without a major adverse event) with missing information for MPA pressure.
cohort from the IMPACT Registry. This risk-standardization model can lay the foundation for comparing outcomes across institutions participating in IMPACT while accounting for the types of patients they treat and the types of procedures they perform. By incorporating risk-standardized outcomes into the IMPACT quarterly metrics report, an equitable method for outcome assessment, benchmarking, and quality improvement can be provided to IMPACT participants.
This study extends previous efforts to develop riskstandardization models for congenital cardiac catheterization. The first attempt at risk standardization was a single-center initiative performed at Boston Children's Hospital, designed to develop a risk model for preventable and possibly preventable adverse events. Given its development at a single center, the tool was designed as a means to equitably compare outcomes among different practitioners within the same institution. The model, however, had C-statistics ranging from 0.65 to 0.74, and it was acknowledged that other important variables likely had not been identified, which may help in improving model discrimination. 21 The next step in model development was expansion to a multicenter dataset and creation of the CHARM model, which laid an important foundation for the current project. Using data from 8 centers and ≈10 000 procedures, the investigators created a model for comparison of outcomes between institutions. Within their model, the investigators adjusted for procedural complexity (eg, proceduretype risk category), hemodynamic vulnerability, and <1 year of age. 2 Development of a risk-standardization model for the IMPACT Registry required expanding on work done as part of these previous risk-standardization efforts. The first goal was to explore whether the variables in the CHARM model could be applied directly to data from IMPACT. 3 Directly applying the procedure-type risk groups and markers of hemodynamic vulnerability used in CHARM, a preliminary model for occurrence of an MAE was created. This initial model adjusted for age, single-ventricle physiology, renal insufficiency, procedure-type risk group, and hemodynamic vulnerability. This preliminary risk model had reasonable discrimination (C-statistic 0.70). However, given that the hemodynamic vulnerability and procedure-type risk group variables were developed using data from the Congenital Cardiac Catheterization Project on Outcomes dataset and created using alternative criteria for defining an MAE, it was acknowledged that additional work would be needed before this risk model would be suitable for quality reporting back to sites participating in IMPACT. 3 The primary goal in this project was to create a unique risk adjustment methodology for an MAE composite outcome as defined in the IMPACT Registry. This current model was developed on a dataset that includes a broader number of centers, refines the stratification of procedure types and hemodynamics for better discrimination of the outcome, and was validated in an independent cohort. Additionally, given the relatively low number of cases submitted during the early years of the registry and a steady increase in the number of centers submitting data to IMPACT over time, the size of the study cohort nearly doubled compared with the initial risk model. These refinements have helped to ensure that this risk model will accurately adjust for patient acuity and procedural complexity and provide individual centers an accurate reflection of how their outcomes compare with other centers.
Implementation of a risk model for outcomes after catheterization of pediatric and adult patients with CHD is an important step in improving the quality of care for this patient population. The reporting of riskstandardized rates of adverse events is important not only for hospitals seeking to improve their own practice patterns and outcomes but also for patients. In an era when transparency and public reporting of outcomes are becoming increasingly embraced, the ability to report risk-standardized rates of MAEs is crucial. Individual practitioners and institutions are much more likely to support public reporting if they feel that these data represent a fair and accurate assessment of their performance and reflect the acuity of their patient population. Within other domains of pediatric cardiology, including pediatric cardiac surgery, these types of risk models have been of great value.
In the initial development of a risk-standardization model for IMPACT, a more limited definition of adverse events was utilized. For this project, the definition of adverse events was broadened to include things such as bleeding and arrhythmia. As a result, the rate of adverse events for the present study is higher compared with our initial work. In this study, death was also included in the composite end point, unlike in initial work, where 1 model was inclusive of death and a separate model excluded death. 3 The inclusion of death in the assessment of outcomes for patients with CHD undergoing cardiac catheterization has been widely debated, particularly in light of other studies demonstrating that mortality in patients with CHD undergoing cardiac catheterization is rarely attributable to the cardiac catheterization procedure. 9 Although in this model we risk the possibility of identifying deaths that were unrelated to the cardiac catheterization, excluding death from the composite end point could result in overlooking instances in which complications from a cardiac catheterization resulted in death after the procedure. Although it is estimated that only 10% of deaths after cardiac catheterization can be attributed to the procedure, 9 these cases should not be overlooked because death after cardiac catheterization is certainly an event that should prompt further review. Furthermore, the ultimate goal of this risk model is to improve quality of care for this patient population, and examining deaths after cardiac catheterization, regardless of attribution, has the potential to identify areas for improvement in care, even if death is caused by processes that occur after the catheterization procedure. Certain potential limitations should be considered when interpreting the findings of this study. First, this study represents data only from those centers participating in the IMPACT Registry and may not be reflective of all centers. Participation in the IMPACT Registry reflects a commitment to quality improvement, and practice patterns may be different at nonregistry hospitals. However, IMPACT is the largest clinical registry to date collecting information on pediatric and adult patients with CHD, and with >70 hospitals in the study population, it represents the majority of hospitals nationally performing such procedures. Second, this risk model was designed for identification of MAEs and did not include an assessment of procedural effectiveness. It is possible that more risk-averse centers have lower rates of adverse events but may also have lower rates of procedural success. For example, a center that is more aggressive with regard to balloon valvuloplasty for treatment of aortic or pulmonic stenosis may have higher rates of valvular regurgitation after the procedure and therefore higher risk-standardized adverse event rates. This same center, however, may achieve much lower gradients after the procedure, obviating the need for further catheterization or surgical procedures. Therefore, the findings of this study can be used only to identify centers with the lowest risk-standardized rates of adverse events and cannot necessarily be used to identify centers that perform well in all aspects of catheterization-related care. Third, as with all observational studies, there is certainly the potential for unmeasured confounding, and there were potentially factors that increased the likelihood of an adverse event, for which we did not adjust. Fourth, this risk model was developed within IMPACT version 1, and since development, the IMPACT Registry has implemented version 2. In the future, longitudinal performance in IMPACT version 2 will need to be assessed. Last, the study was conducted on deidentified registry data, and we did not have the ability to verify accurate coding, including coding of data on adverse events. However, the outcomes that were selected for inclusion in the composite end point are end points that are likely to be recorded within the medical record and are unlikely to be subject to individual interpretation. Additionally, given the rigorous quality assurance standards of the registry and periodic data audits, we have no reason to believe that inaccuracies in data abstraction influenced the findings of the study.
Conclusions
We have described a robust risk-standardization methodology for the IMPACT Registry, creating a model that can be incorporated into the IMPACT quarterly metric reports. In this work, we improved on previous risk-standardization efforts by deriving model variables specific to IMPACT data collection and reporting for an important outcome in the population: MAEs. We believe that this model can be a valuable tool for the CHD interventional community to help hospitals critically evaluate their performance compared with other centers, and serve as a foundation for improving procedural outcomes.
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